Klotho mRNA Therapeutic

About Klothea Bio

Klothea Bio is an early-stage biotech pioneering mRNA-based therapies targeting the aging-associated Klotho protein. The company's core technology combines a proprietary, highly effective mRNA construct with novel, safe nanocarriers designed for repeat dosing, differentiating it from conventional mRNA vaccine approaches. With a lead program targeting metabolic syndrome, Klothea is preparing for Phase 1 clinical trials in early 2026 and has established a partnership with the Healthy Longevity clinic, a semifinalist in the XPRIZE Healthspan competition. The company is backed by a world-class Scientific Advisory Board including the discoverer of the Klotho protein, Dr. Makoto Kuro-o.

Therapeutic Areas

Other Metabolic Syndrome Drugs